These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8383900)

  • 21. Drug misuse treatment services in Scotland: predicting outcomes.
    Morris ZS; Gannon M
    Int J Qual Health Care; 2008 Aug; 20(4):271-6. PubMed ID: 18492708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Needs assessment in substance misuse: a comparison of approaches and case study.
    Simeone RS; Frank B; Aryan Z
    Int J Addict; 1993 Jun; 28(8):767-92. PubMed ID: 8394288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The role of specialized treatment in school's substance use and misuse].
    Romailler M; Charpentier P; Graap C; Khosrov P; Stachel R
    Rev Med Suisse; 2006 Jun; 2(69):1526-9. PubMed ID: 16833095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Do specialized services exist for LGBT individuals seeking treatment for substance misuse? A study of available treatment programs.
    Cochran BN; Peavy KM; Robohm JS
    Subst Use Misuse; 2007; 42(1):161-76. PubMed ID: 17366131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using concept mapping to design an indicator framework for addiction treatment centres.
    Nabitz U; van Den Brink W; Jansen P
    Int J Qual Health Care; 2005 Jun; 17(3):193-201. PubMed ID: 15831547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and correlates of drug use disorders in Mexico.
    Medina-Mora ME; Borges G; Fleiz C; Benjet C; Rojas E; Zambrano J; Villatoro J; Aguilar-Gaxiola S
    Rev Panam Salud Publica; 2006 Apr; 19(4):265-76. PubMed ID: 16723068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Algorithms for resource allocation of substance abuse prevention funds based on social indicators: a case study on state of Florida--Part 3.
    Kim S; Wurster L; Williams C; Hepler N
    J Drug Educ; 1998; 28(4):283-306. PubMed ID: 10097481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The health of adolescents in Switzerland].
    Michaud PA; Ambresin AE
    Praxis (Bern 1994); 2013 Sep; 102(18):1111-6. PubMed ID: 24005070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral healthcare's new horizon.
    Dorna H
    Behav Healthc; 2007 May; 27(5):27-9. PubMed ID: 17958241
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of program services on treatment outcomes of patients with comorbid mental and substance use disorders.
    Grella CE; Stein JA
    Psychiatr Serv; 2006 Jul; 57(7):1007-15. PubMed ID: 16816286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is universal prevention against youths' substance misuse really universal? Gender-specific effects in the EU-Dap school-based prevention trial.
    Vigna-Taglianti F; Vadrucci S; Faggiano F; Burkhart G; Siliquini R; Galanti MR;
    J Epidemiol Community Health; 2009 Sep; 63(9):722-8. PubMed ID: 19395396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug misuse services. No quick fixes.
    Thomson R; Bellis M
    Health Serv J; 1997 Oct; 107(5576):30-1. PubMed ID: 10174936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abuse and Misuse of Prescription and Nonprescription Drugs from Community Pharmacies in Aden City-Yemen.
    Abood EA; Wazaify M
    Subst Use Misuse; 2016 Jun; 51(7):942-7. PubMed ID: 27100671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mobility of hard drug users: patterns and characteristics relevant for deconcentration of facilities.
    van de Mheen D; van der Poel A; Lempens A; Maalsté N
    J Psychoactive Drugs; 2007 Jun; 39(2):191-9. PubMed ID: 17703714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Programme base for the prevention of drug abuse in Yugoslavia.
    Skrlj M
    Bull Narc; 1986; 38(1-2):105-12. PubMed ID: 3779176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of pregnancy on psychoactive substance use among women with substance use disorders recruited in addiction specialized care centers in France.
    Pochard L; Dupouy J; Frauger E; Giocanti A; Micallef J; Lapeyre-Mestre M;
    Fundam Clin Pharmacol; 2018 Apr; 32(2):188-197. PubMed ID: 29337399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safer injection facilities for injection drug users: the debate continues.
    de Vlaming S
    CMAJ; 2002 Feb; 166(4):419; author reply 422, 424-5. PubMed ID: 11873915
    [No Abstract]   [Full Text] [Related]  

  • 39. Guiding principles of drug demand reduction: an international response.
    Ghodse H
    Br J Psychiatry; 1999 Oct; 175():310-2. PubMed ID: 10789294
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.